NCT03538951View on ClinicalTrials.gov

Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

December 10, 2018

Study Completion Date

December 10, 2018

Conditions
Actinic Keratosis
Interventions
DRUG

10% VDA-1102

200 mg twice-daily for 12 weeks

DRUG

20% VDA-1102

200 mg once-daily for 12 weeks

Trial Locations (1)

92123

Therapeutics Clinical Research, San Diego

Sponsors

Lead Sponsor

Vidac Pharma

Collaborators (1)

PharPoint Research, Inc.
All Listed Sponsors
collaborator

Therapeutics, Inc.

INDUSTRY

collaborator

PharPoint Research, Inc.

INDUSTRY

collaborator

Medistat Ltd., Israel

INDUSTRY

lead

Vidac Pharma

INDUSTRY